fashion -WSS

fashion

author：hotspot 2025-09-28 08:32:50 - browse：32

Eli Lilly headquarters — Kristoffer Tripplaar/AP

The drug giant Eli Lilly said Thursday that its diabetes drug Mounjaro helped patients with the condition lose 15.7% of their body weight in a clinical trial, a result that Wall Street analysts expect to pave the way for the therapy’s approval as a weight loss treatment.

Mounjaro is the latest drug in a class known as GLP-1s or incretins — the same class as Novo Nordisk’s Ozempic, which has become a sensation because of its ability to help patients lose weight. Mounjaro has shown the potential to lead to even greater weight loss than Ozempic, and industry experts expect that it will eventually generate many billions of dollars in annual sales. Analysts at SVB Securities projected in December that Mounjaro sales could reach $26.4 billion by 2030.

Eli Lilly on Thursday also announced quarterly earnings of $1.64 per share, adjusted for one-time items, slightly below analyst expectations, on sales of $6.96 billion. Sales were hurt because of a comparison to a year ago, when the company’s Covid-19 monoclonal antibodies were still on the market. Mounjaro sales for the first quarter were $586 million, largely for people with diabetes, compared to an analyst consensus of $433.2 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Beach reads and more: STAT's 2023 summer book list

WSS

Acelyrin, a rare IPO success, stumbles in its first big test

HCA discloses massive data breach affecting 11 million patients

Pig kidney works a record two months in donated body

FDA panel endorses Alnylam’s heart drug — after picking it apart

How to make the FDA’s new prescription one

Pig kidney works a record two months in donated body

hotspot

fashion

leisure time

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Why ADHD is under

New air purifier tech could be key to improving indoor air quality

Living with Fabry disease, a condition that causes chronic pain

ChatGPT in medicine: STAT answers readers' burning questions

Beach reads and more: STAT's 2023 summer book list

FDA approval of Sarepta Duchenne genetic therapy gives me hope

How to make the FDA’s new prescription one

Trump demands the U.S. pay no more for drugs than other countries … again

How the political right came to back psychedelics to treat trauma

focus

Will the IRA bring competition to the biologics market?

Beach reads and more: STAT's 2023 summer book list

Lecanemab for Alzheimer's is coming. Is the health system ready?

How the political right came to back psychedelics to treat trauma

Hospitals consider fixing cancer drug shortages on their own

FDA panel endorses Alnylam’s heart drug — after picking it apart

leisure time

explore

focus

entertainment